Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R, Michon J, Pritchard J, Klingebiel T, Kremens B, Pearson A, Coze C, Paolucci P, Frappaz D, Gadner H, Chauvin F
Biostatistics Unit, Coordinating Center of the European Bone Marrow Transplantation Solid Tumor Working Party, Centre Léon Bérard, Lyon, France.
J Clin Oncol. 1998 Mar;16(3):953-65. doi: 10.1200/JCO.1998.16.3.953.
The European Bone Marrow Transplantation (EBMT) Solid Tumor Registry (STR) contains detailed information on children with advanced neuroblastoma who, after standard-dose induction chemotherapy and surgery, received myeloablative megatherapy (MGT) followed by stem-cell transplantation (SCT). This data base was analyzed to identify factors that predict event-free survival (EFS).
Eligibility criteria were stage IV neuroblastoma, age over 1 year at diagnosis, and no relapse before MGT/SCT. Between February 1978 and July 1992, 549 patients were registered by 36 European transplant centers. The median age at diagnosis was 36 months (range, 13 to 216 months) and the male-female ratio was 1:45. Before MGT, 157 patients were in complete remission (CR), 156 in very good partial remission (VGPR), and 208 in partial remission (PR), whereas 24 had had only a minor response (MR). One hundred ten of 546 patients had undergone two successive MGT procedures. The median observation time was 60 months (range, 12 to 187 months).
Actuarial EFS is 26% at 5 years. Multivariate analysis by the Cox proportional hazards regression model included 529 patients with complete data sets. After adjustment for treatment duration before MGT and double MGT procedures, two adverse, independent risk factors that influenced EFS were identified: (1) persisting skeletal lesions before MGT as defined by technetium (99TC) scans and/or meta-iodobenzylguanidine (mIBG) scans (P = .004) and (2) persisting bone marrow involvement before MGT (P = .03).
After induction treatment, persisting skeletal disease as defined above and persisting bone marrow involvement may be predictive of a particularly poor outcome. Physicians may consider this an additional important tool to decide the patient's management.
欧洲骨髓移植(EBMT)实体瘤登记处(STR)包含了晚期神经母细胞瘤患儿的详细信息,这些患儿在接受标准剂量诱导化疗和手术后,接受了大剂量清髓疗法(MGT),随后进行了干细胞移植(SCT)。对该数据库进行分析,以确定预测无事件生存期(EFS)的因素。
入选标准为IV期神经母细胞瘤、诊断时年龄超过1岁且在MGT/SCT前无复发。1978年2月至1992年7月期间,36个欧洲移植中心登记了549例患者。诊断时的中位年龄为36个月(范围13至216个月),男女比例为1:45。在MGT前,157例患者处于完全缓解(CR),156例处于非常好的部分缓解(VGPR),208例处于部分缓解(PR),而24例仅有微小反应(MR)。546例患者中有110例接受了两次连续的MGT程序。中位观察时间为60个月(范围12至18个月)。
5年时的精算EFS为26%。采用Cox比例风险回归模型进行多变量分析,纳入了529例有完整数据集的患者。在对MGT前的治疗持续时间和双重MGT程序进行调整后,确定了两个影响EFS的不良独立危险因素:(1)MGT前由锝(99TC)扫描和/或间碘苄胍(mIBG)扫描定义的持续骨骼病变(P = 0.004)和(2)MGT前持续的骨髓受累(P = 0.03)。
诱导治疗后,上述定义的持续骨骼疾病和持续的骨髓受累可能预示着特别差的预后。医生可将此视为决定患者治疗方案的另一个重要工具。